Skip to main content
. Author manuscript; available in PMC: 2012 Jun 1.
Published in final edited form as: Cancer Prev Res (Phila). 2011 Mar 16;4(6):897–906. doi: 10.1158/1940-6207.CAPR-10-0323

Fig. 1.

Fig. 1

A, immunoblotting for XIAP, survivin, and cIAP1 proteins using lysates from PC-3 and LNCaP cells treated for 8- or 16-hours with DMSO (control) or the indicated concentrations of DATS. Blots were stripped and re-probed with anti-actin antibody to correct for differences in protein loading. B, reverse transcription-PCR for XIAP and survivin in PC-3 and LNCaP cells treated for 8- or 16-hours with DMSO or the indicated concentrations of DATS. C, immunoblotting for XIAP protein using lysates from PC-3 and LNCaP cells treated for 16-hours with the indicated concentration of DATS in the absence or presence of the indicated concentration of proteasomal inhibitor MG132. Each experiment was repeated at least twice, and representative data from one such experiment are shown.